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Abstract
Introduction:  C-reactive  protein  (CRP)  and  Bedside  Index  for  Severity  in Acute  Pancreatitis
(BISAP)  have  been  used  in early  risk  assessment  of patients  with  AP.
Objectives:  We  evaluated  prognostic  accuracy  of  CRP  at 24  hours  after  hospital  admission
(CRP24) for  in-hospital  mortality  (IM)  in AP  individually  and  with  BISAP.
Materials  and  Methods:  This  retrospective  cohort  study  included  134  patients  with  AP
from a  Portuguese  hospital  in 2009--2010.  Prognostic  accuracy  assessment  used  area  under
receiver--operating  characteristic  curve  (AUC),  continuous  net  reclassification  improvement
(NRI),  and integrated  discrimination  improvement  (IDI).
Results:  Thirteen  percent  of  patients  had  severe  AP,  26%  developed  pancreatic  necrosis,  and  7%
died during  index  hospital  stay.  AUCs  for  CRP24  and BISAP  individually  were  0.80  (95%  confidence
interval (CI)  0.65--0.95)  and  0.77  (95%  CI 0.59--0.95),  respectively.  No patients  with  CRP24
<60 mg/l  died  (P = 0.027;  negative  predictive  value  100%  (95%  CI 92.3--100%)).  AUC  for  BISAP
plus CRP24  was  0.81  (95%  CI 0.65--0.97).  Change  in NRInonevents (42.4%;  95%  CI, 24.9--59.9%)
resulted in positive  overall  NRI  (31.3%;  95%  CI, −36.4%  to  98.9%),  but  IDInonevents was  negligible
(0.004;  95%  CI,  −0.007  to  0.014).
Abbreviations: AP, acute pancreatitis; AUC, area under receiver--operating curve; BISAP, Bedside Index for Severity in Acute Pancreatitis;
CECT, contrast enhanced computed tomography; CI,  confidence interval; CRP, C-reactive protein; CRP24, C-reactive protein at 24 hours after
hospital admission; IDI, integrated discrimination improvement; IM, in-hospital mortality; NRI, continuous net reclassification improvement;
OR, odds ratio; SAP, severe acute pancreatitis; STROBE, Strengthening the Reporting of Observational Studies in Epidemiology.
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Conclusions:  CRP24  revealed  good  prognostic  accuracy  for  IM  in  AP;  its main  role  may  be the
selection  of  lowest  risk  patients.
© 2015  Sociedade  Portuguesa  de Gastrenterologia.  Published  by  Elsevier  España,  S.L.U.  This  is
an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Valor  Prognóstico  da  Proteína-C  Reativa  às  24  Horas  após  a  Admissão  Hospitalar  na
Pancreatite  Aguda:  Um  Estudo  Coorte  Retrospetivo
Resumo
Introduc¸ão: A  proteína-C  reativa  (CRP)  e o  Bedside  Index  for  Severity  in Acute  Pancreatitis
(BISAP) têm  sido usados  na  avaliac¸ão  de risco  precoce  de  doentes  com  pancreatite  aguda  (AP).
Objectivos: Nós  avaliámos  o valor  prognóstico  da  CRP  às  24  horas  após  a  admissão  hospitalar
(CRP24) na  mortalidade  intrahospitalar  (IM)  na  AP,  individualmente  e  com  o  BISAP.
Materiais  e  Métodos:  Este  estudo  coorte  retrospetivo  incluiu  134 doentes  com  AP  de  um  hos-
pital português  em  2009--2010.  A  acuidade  prognóstica  foi avaliada  usando  a  área  debaixo  da
receiver-operating  characteristic  curve  (AUC),  o continuous  net reclassification  improvement
(NRI), e  o  integrated  discrimination  improvement  (IDI).
Resultados:  Treze  por  cento  dos  doentes  tiveram  AP  grave,  26%  desenvolveram  necrose  pan-
creática, e 7%  morreram  durante  a hospitalizac¸ão  índice.  As  AUCs  da  CRP24  e do BISAP
individualmente  foram  0,80  (intervalo  de  confianc¸a  (IC)  95%,  0,65--0,95)  e 0,77  (IC 95%,
0,59--0,95),  respectivamente.  Nenhum  doente  com  CRP24  <60  mg/l  morreu  (P  =  0,027;  valor
predictivo  negativo  100%  (IC  95%,  92,3--100%)).  A  AUC  para  o  BISAP  mais  a  CRP24  foi 0,81  (IC
95%, 0,65--0,97).  A mudanc¸a no  NRI-não-eventos  (42,4%;  IC 95%,  24,9--59,9%)  resultou  num  NRI-
total positivo  (31,3%;  IC 95%,  −36,4  a  98,9%),  mas num  IDI-não-eventos  negligenciável  (0,004;
IC 95%,  −0,007  a  0,014).
Conclusões:  A CRP24  revelou  um  valor  prognóstico  bom  para  a  mortalidade  intrahospitalar  na
AP; o  seu  papel  principal  poderá  ser  a  selecc¸ão  dos  doentes  de  menor  risco.
© 2015  Sociedade  Portuguesa  de Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.U.  Este  é
um artigo  Open  Access  sob  a  licença  de CC BY-NC-ND  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
1. Introduction
The  incidence  of  acute  pancreatitis  (AP)  seems  to  be
increasing  in several  countries.1,2 Most  cases  of  disease
follow  a  course  without  complications,  but  about  20%  of
patients  develop  severe  AP  (SAP).3 The  overall  mortality  is
2.1--7.8%,  but SAP  leads  to  prolonged  hospitalization  and
higher  mortality.4,5
The  early  risk  assessment  of  patients  with  AP  by  accurate
and  reliable  methods  is  necessary  to  improve  clinical  out-
comes  and  reduce  costs  of  treatment.  Several  tools  for the
early  risk  assessment  of  these  patients  have  been  developed;
they  include  single  biochemical  markers,  imaging  methods,
and  complex  scoring  systems.6
C-reactive  protein  (CRP)  is  an acute  phase  reactant  that
has  been  largely  used in  the  early  risk  assessment  of  patients
with  AP.  Among  single  biochemical  markers,  CRP  remains  the
most  useful  in  predicting  SAP,  especially  due  to  its  accuracy
and  accessibility.6,7 Despite  these  advantages,  its prognostic
accuracy  has  been  validated  for  measurements  no  sooner
than  36  hours  after  hospital  admission.8,9 In this regard,
some  other  tools for  earlier  risk  assessment  of  patients  with
AP,  as  Bedside  Index  for  Severity  in AP  (BISAP),  might  be
more  useful.10
BISAP  has  been  validated  as an accurate  and  reliable
scoring  system  for early  identification  of  patients  with
AP  at risk  for  in-hospital  mortality  (IM).10--12 It  comprises
the  assessment  of  5 clinical  variables  in the  first  24  hours
after  hospital  admission:  Blood  urea  nitrogen  greater  than
25  mg/dl;  presence  of  impaired  mental  status  on  clinical
evaluation;  presence  of  systemic  inflammatory  response
syndrome;  age greater  than 60  years;  presence  of  pleural
effusion  on  clinical  or  radiological  evaluation.  The  index
final  score  is  calculated  by  adding  one  point  per  each  vari-
able  present  (out  of  5  points).  According  to  this scoring
system,  IM  increases  progressively  with  its  final  score,  being
5--20% for  a final  score  equal  or  greater  than  3  points.10
In this  study,  we  hypothesized  that  CRP  measured  at
24  hours  after  hospital  admission  (CRP24)  may  have  rele-
vant  prognostic  value  for  IM  in AP and  this  may  add  to  the
one  from  BISAP.  Accordingly,  we  aimed  to  determine  CRP24
individual  prognostic  accuracy  for  IM  in AP and  identify  a
clinically  significant  cutoff  point;  additionally,  we  sought  to
quantify  the combined  prognostic  accuracy  for  IM  in  AP  of
CRP24  and  BISAP.
2.  Materials and Methods
The  reporting  of  this study  followed  the  Strengthening
the  Reporting  of  Observational  Studies  in Epidemiology
(STROBE)  statement.13 The  local  Health  Research  Ethics
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Board  approved  this  study  and  the requirement  for  individual
informed  consent  was  waived.
2.1.  Design, setting,  participants,  and data
collection
This  was  a  single  center  retrospective  cohort  study  which
included  initially  all  patients  consecutively  admitted  to
the  emergency  department  of  a Portuguese  general  dis-
trict  hospital  (Hospital  Professor  Doutor  Fernando  Fonseca,
Amadora)  with  AP  between  January  2009  and December
2010.  Of  this  set,  patients  with  incomplete  data  on  CRP24,
BISAP  score,  or  in-hospital  final  vital status  were  excluded.
Patients  were identified  from  the hospital’s  diagnostics
dedicated  computerized  database.  Demographic  and clini-
cal  data  were  collected  by  3  investigators  from  a  variety  of
sources  including  patients’  charts  (manual  and  electronic),
laboratory  reports,  and radiology  reports.
2.2.  Operational  definitions
The  diagnosis  of  AP  was  made  if 2  of the following  3 fea-
tures  were  present:  (i)  Abdominal  pain  suggestive  of AP;
(ii)  serum  amylase  and/or  lipase  activity  at least  3 times
greater  than  the  upper  limit  of  normal;  and  (iii)  charac-
teristic  findings  of AP  on  transabdominal  ultrasonography
or  on contrast-enhanced  computed  tomography  (CECT).14
Despite  these  criteria,  all  patients  in whom  the minimum
3-fold  hyperamylasemia  was  proved  to  be  from  other  cause,
rather  than  AP,  were  excluded.
Patients  were  classified  as  SAP  if organ  failure  was
present  for  more  than  48 hours.  In accordance  to  the Mar-
shall  Scoring  System,  organ  failure  includes  at  least  one  of
the  following  features:  (i)  Respiratory  failure,  defined  as
PO2/FiO2  ≤300  mmHg;  (ii) renal  failure,  defined  as  serum
creatinine  level ≥1.9 mg/dl;  and (iii)  shock,  defined  as  sys-
tolic  blood  pressure  <90 mmHg  and unresponsive  to  fluid
therapy.14
As  a  local  complication,  PNec  was  diagnosed  by  CECT
when  there  was  lack  of  enhancement  of  pancreatic
parenchyma  after  contrast  infusion.14
For  each  patient,  all CRP  determinations  obtained  during
the  first  24  hours  after  hospital  admission  were  collected  and
only  the  greatest  level  of  those  was  considered  for analysis.
These  CRP  determinations  were  obtained  using  the  standard
technique  at  the  hospital’s  laboratory  (Dimension  Vista  Sys-
tem,  Flex  reagent  cartridge,  Siemens  Healthcare  Diagnostics
Products,  Germany)  and  expressed  in mg/l.
BISAP  score  was  determined  according  to  what  has been
previously  published.10
2.3.  Primary  exposures and  primary  outcome
Primary  exposures  were  CRP  level and BISAP  score  in the
first  24  hours  after  hospital  admission.  Primary  outcome
was  IM,  which  referred  to  death  occurring  from  AP  or  its
complications  (inflammatory,  septic,  morphological  or  oth-
ers)  during  index  hospital  stay.
2.4.  Statistical  analysis
Categorical  variables  were  presented  as  frequencies  and
percentages  and  continuous  variables  as  median  and  inter-
quartile  range  (percentile  25--percentile  75) or  range
(minimum--maximum).  Missing  data  were not  replaced  or
estimated.
Univariable  analysis  used  nonparametric  tests  (Chi-
square,  Fisher’s  Exact,  Mann--Whitney  U)  due  to  the
existence  of  outliers  and  skewed  distributions.  Logistic
regression  models  were  used to  evaluate  the  prognostic
accuracy  of CRP24  and  BISAP  for  IM  with  odds  ratios  (ORs)
being  calculated  after  cross-validation.  Discriminative  abil-
ity  was  assessed  by  the  area  under  the  receiver--operating
characteristic  curve  (AUC)15 and comparison  between  AUCs
was  made  using the method  described  by  DeLong  et  al.16
To  compensate  for possible  shortcomings  of  AUC  analysis
in quantifying  the added  value  of  a  biomarker  to  an  exist-
ing  test,  continuous  net  reclassification  improvement  (NRI)
and  integrated  discrimination  improvement  (IDI) parameters
were  also  calculated.17,18
All  statistical  tests  were  two-sided  and  P <0.05  was  con-
sidered  statistically  significant.  All  analyses  were performed
with  IBM  SPSS  Statistics,  Version  19.0  (IBM  Corp.,  North  Cas-
tle,  New  York,  USA)  and  Stata/IC  12.0  (Statacorp.  LP,  College
Station,  TX,  USA).
3.  Results
3.1.  Patients’  characteristics
A  total  of  299  patients  were  initially  included.  Of  this  set,
only  134  patients  (44.8%)  had  complete  data  on  CRP24,
BISAP,  and  in-hospital  final  vital  status  and  were subse-
quently  considered.
Median  age was  64  years  (range,  13--96  years),  with  80
men  (59.7%).  Biliary  lithiasis  was  the  most frequent  iden-
tifiable  cause  of  AP  with  59  patients  (44.0%).  Of  a  total
of  70  patients  (52.2%)  with  complete  data  on  organ  fail-
ure  parameters,  9  (12.9%)  developed  organ failure  for  more
than  48  hours  and  were  classified  as  having  SAP.  CECT  was
performed  in 91  patients  (67.9%) and  in  24  of  those  (26.4%)
pancreatic  necrosis  was  found.  Median  day  for CECT  per-
formance  was  the  fourth  day  of  hospital  stay  (range,  1--26
days).  From  the  70  patients  with  Marshall  score  evaluation,
51  (72.9%)  underwent  CECT;  from  the  9 patients  with  SAP,
4  (44.4%)  were  diagnosed  with  pancreatic  necrosis.  Median
length  of  hospital  stay  was  9 days  (range,  1--80 days).  Nine
patients  (6.7%)  died  during  index  hospital  stay.  Median  time
to  death  was  15  days  (range,  1--60 days).
3.2.  CRP24  prognostic  accuracy  for IM
Median  overall  CRP24  level was  104.4  (inter-quartile  range,
29.2--191.2  mg/l)  and  its  distribution  by  IM  status  is  shown  in
Fig.  1.  Median  CRP24  level  was  higher  in patients  who  died
during  index hospital  stay  (197.2  vs.  100.2,  p  =  0.003).  CRP24
univariable  OR  for  IM  was  1.11  (95%  CI,  1.04--1.17)  and  corre-
sponding  AUC was  0.80  (95%  CI,  0.65--0.95).  Analysis  of  the
coordinate  points  of the receiver--operating  characteristic
curve  showed  that,  from  the  46 patients  with  a  CRP24  level
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Fig.  1  Distribution  of  patients  by  C-reactive  protein  at
24 hours  after  hospital  admission  (CRP24)  level  and  in-hospital
mortality  (IM)  status.
lower  than  60 mg/l,  none  died  (p  =  0.027).  Additionally,  from
the  9  patients  with  SAP,  only one  (11.1%)  had  a CRP24  level
lower  than  60  mg/l.  This  CRP24  cutoff  point yielded  the fol-
lowing  sensitivity,  specificity,  negative  predictive  value,  and
positive  predictive  value  for  IM:  100%  (95% CI, 66.4--100%),
36.8%  (95%  CI, 28.4--45.9%),  100%  (95%  CI,  92.3--100%),  and
10.0%  (95%  CI,  4.8--18.5%),  respectively.
3.3.  BISAP  prognostic  accuracy  for IM
The  distribution  of patients  by  BISAP  categories  is  shown
in  Fig.  2. Twenty-three  patients  (17%)  had  a  BISAP  score
equal  or  greater  than  3. BISAP  univariable  OR  for  IM  was
2.27  (95%  CI, 1.37--3.77)  and  corresponding  AUC  was  0.77
(95%  CI,  0.59--0.95).
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Fig.  2  Distribution  of  patients  by  Bedside  Index  for  Severity
in Acute  Pancreatitis  (BISAP)  categories.
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Fig.  3 Receiver--operating  characteristic  curve  (ROC)  of  Bed-
side  Index  for  Severity  in Acute  Pancreatitis  (BISAP;  full line)
and BISAP  plus  C-reactive  protein  at 24  hours  after  hospital
admission  (CRP24;  dashed  line)  prognostic  accuracy  for  in-
hospital  mortality  (IM).  BISAP  area  under  ROC  (AUC)  of  0.77
(95% CI, 0.59--0.95)  and  BISAP  plus  CRP24  AUC  of  0.81  (95%  CI,
0.65--0.97).
3.4.  BISAP  plus CRP24  model  prognostic  accuracy
for IM
After  cross-validation,  BISAP  plus  CRP24  model  ORs  for  IM
were  1.77  (95%  CI, 1.05--3.00)  for  BISAP  and  1.09  (95%  CI,
1.02--1.16)  for  CRP24;  corresponding  AUC  was  0.81  (95%  CI,
0.65--0.97).  AUCs  of  BISAP  alone  and  BISAP  plus  CRP24  model
were  not  significantly  different  (Fig.  3:  P  =  0.62).
Statistics  of BISAP  prognostic  accuracy  for  IM  improve-
ment  with  the addition  of  CRP24  are summarized  in Table  1.
The  overall  reclassification  of  patients  (NRI)  was  mainly  due
to  the reclassification  of survivors  (non-events),  as  absolute
NRInonevents was  greater  than  NRIevents. In fact,  the  NRInonevents
showed  a significant  change  (42.4%; 95%  CI, 24.9--59.9%)
which  resulted  in  a positive  overall  NRI  (31.3%;  95%  CI, −36.4
to  98.9%),  but  the IDInonevents was  negligible,  with  a 95%  CI
straddling  zero  (0.004;  95%  CI, −0.007  to 0.014).  This  means
that  the addition  of CRP24  to  BISAP  reduced  the  calculated
risk  of IM  in about 42%  of  patients  who  survived,  albeit  the
overall  effect  was  not  statistically  significant.
4.  Discussion
In  this study, we  found  that  CRP24  may  be a  useful  biochem-
ical  marker  for  the  early  risk  assessment  of  patients  with
AP.
CPR24  showed  good  individual  prognostic  accuracy  for  IM
in  AP.  Moreover,  the evaluation  of  a possible  cutoff  point
with  clinical  relevance  revealed  that  60  mg/l  warranted  a
negative  predictive  value  of 100%,  meaning  that  patients
with  AP  and  a  CRP24  level  lower  than  that  cutoff  point
were  not at risk  of  dying from  AP  or  its  complications  dur-
ing  the following  hospital  stay.  The  low prevalence  of IM  in
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Table  1  Statistics  of  BISAP’s  prognostic  accuracy  for  in-
hospital  mortality  in acute  pancreatitis  improvement  with
the addition  of CRP24.
Statistics  Coefficient  (95%  CI)
AUC
BISAP  0.77  (0.59--0.95)
BISAP +  CRP24  0.81  (0.65--0.97)
NRI (%)
NRIevents −11.1  (−76.4  to  54.2)
NRInonevents 42.4  (24.9--59.9)
NRIa 31.3  (−36.4  to  98.9)
IDI
IDIevents 0.029  (−0.115  to  0.173)
IDInonevents 0.004  (−0.007  to  0.014)
IDIb 0.033  (−0.112  to  0.177)
CI, confidence interval; AUC, area under receiver--operating
curve; BISAP, Bedside Index for Severity in Acute Pancreatitis;
CRP24, C-reactive protein at 24 hours after hospital admission;
NRI, continuous net reclassification improvement; IDI, inte-
grated discrimination improvement; Events, patients that died;
Nonevents, patients that survived.
a NRI equals NRIevents plus NRInonevents.
b IDI equals IDIevents plus IDInonevents.
this  population-based  study  may  have  precluded  the deter-
mination  of a cutoff  point with  a  high  positive  predictive
value.19
Adding  CPR24 to  BISAP  may  have  represented  an improve-
ment  in  prognostic  accuracy  for  IM  in AP;  in  this  regard,
the  real  gain  may  have  been  due  to  the reclassification  of
patients  at  low risk  to  die  from  AP  or  its  complications  dur-
ing  index  hospital  stay.  Despite  these  observed  tendencies,
statistical  significance  was  not  achieved.
Overall,  this  study  emphasizes  the role  of CRP24  in the
early  risk  assessment  of  patients  with  AP  individually  and  in
combination  with  BISAP.  These  results  underline  the  possi-
ble  advantages  of  combining  simple  and  accessible  tools  for
clinicians  to  perform  a more  reliable  early  risk  assessment
of  patients  with  AP,  as  it has been  outlined  elsewhere20;
this  may  be  done  not  only by  selecting  patients  at high
risk  for  complications,  but  also  by  identifying  those  within
the  low  risk  subgroup  that  most  probably  will not  develop
complications.  This  approach  may  help  specific  institutional
policies  on  AP  by  improving  efficiency  in patient  manage-
ment  and  resources  utilization.
There  were  some  methodological  limitations  to  this
study.  First,  this was  a  retrospective  analysis  of  prospec-
tively  collected  data  from  a  single  center  and  may  have been
prone  to selection  bias  and  limited  generalization.  Second,
missing  CRP24  determinations,  which  made  the final  sample
size  smaller,  might  have  impacted  negatively  the final  pro-
gnostic  accuracy  results  for  the  BISAP  plus  CRP24  model.  The
methodological  strengths  of  this  study  were mainly  the  com-
munity  based  and  consecutive  admission  of  patients  and  the
additional  use  of  NRI  and  IDI  to  assess  the prognostic  perfor-
mance  of  BISAP  plus  CRP24 model.  In  the future,  prospective
and  properly  powered  studies  should  address  CRP24  pro-
gnostic  accuracy  in AP  and  the possibility  of combining  it
with  BISAP  or  other  early  risk  assessment  tools available  for
patients  with  AP.
In  conclusion,  there  seems to  be  a role  for  CRP24  in the
early  risk  assessment  of  patients  with  AP,  especially  by  iden-
tifying  lowest  risk  patients.
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